Five NCEs Approved In China In 2011: A Closer Look At SFDA’s Progress Report
This article was originally published in PharmAsia News
Executive Summary
China’s SFDA recently released its third annual drug registration report. The agency approved 718 drugs and APIs in 2011, including five NCEs.
You may also be interested in...
China Drug Approvals Up 26%, Mostly Due To Generics
China's State FDA increased drug approvals by more than 26% in 2010, with the boost largely due to an increase in generic drug approvals. The agency also cleared more clinical trials for drugs that treat diseases that have a large societal impact, according to SFDA's second annual report on the status of drug approvals
China's Simcere Beats Out Eisai In Iguratimod Approval For Rheumatoid Arthritis
SHANGHAI- China's State FDA cleared Simcere Pharmaceutical Group's new drug application for Iremod (iguratimod) for rheumatoid arthritis, in the world's first approval of the compound, Simcere announced Aug. 25
After Running Lilly From China, CEO Says Local Commitment, Innovation Remain Priorities
For almost the entire month of March, Eli Lilly & Co. CEO John Lechleiter ran his company from China, a feat that included hosting Lilly's annual global leadership summit in Shanghai, where 150 high-level Lilly execs gathered to get a firsthand look at the country, visiting hospitals and research centers and meeting with government officials